PhD (Dr.rer.nat.) in recombinant antibody technology. Employed since 2018. He did his postdoctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology, Germany. Martin has a broad international experience from executive positions within the biotech industry, including Director of Technology at Axaron Bioscience AG, Heidelberg, Germany, CEO of Affitech (Nasdaq Copenhagen) and CEO of Opsona Therapeutics, Dublin, Ireland. Member of the Board of Anocca, APIM Therapeutics AS and Nextera AS. Born 1961.

Shareholding: 22,400

Conditional Employee Options: Option program 2023/2025: 48,000, Option program 2024/2026: 30,000, Option program 2025/2027: 14,000

/sites/bioinvent/files/bioinvert/investors/corporate-governance/management-team/welcom-martin.png Chief Executive Officer Management Team Off